DIABETIC KETOACIDOSIS IN PATIENTS WITH TYPE 2 DIABETES RECENTLY COMMENCED ON SGLT-2 INHIBITORS: AN ONGOING CONCERN.
Endocr Pract
; 23(4): 506-508, 2017 04 02.
Article
en En
| MEDLINE
| ID: mdl-28437153
ABSTRACT
OBJECTIVE:
Sodium-glucose cotransporter 2 (SGLT-2) inhibitors are increasingly used as an adjunctive treatment for type 2 diabetes. We report the occurrence of diabetic ketoacidosis (DKA) in 3 patients with type 2 diabetes recently commenced on SGLT-2 inhibitors.METHODS:
Clinical presentation, laboratory data, and treatment outcomes of all 3 cases are described.RESULTS:
All 3 patients had documented history of longstanding type 2 diabetes. The presentation in all patients was that of hyperglycaemia, acidosis, and ketosis occurring within 4 weeks of commencing SGLT-2 inhibitors. The risk factors for developing DKA were infection, myocardial infarction, and alcohol excess. DKA resolved within 24 hours of initiating intravenous fluids and insulin in all cases.CONCLUSION:
This case series illustrates the importance of careful patient selection, education, and monitoring when starting this group of antidiabetic medications. ABBREVIATIONS DKA = diabetic ketoacidosis SGLT-2 = sodium-glucose cotransporter 2 T2D = type 2 diabetes.
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Cetoacidosis Diabética
/
Diabetes Mellitus Tipo 2
/
Inhibidores del Cotransportador de Sodio-Glucosa 2
/
Hipoglucemiantes
Tipo de estudio:
Risk_factors_studies
Límite:
Aged
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Endocr Pract
Asunto de la revista:
ENDOCRINOLOGIA
Año:
2017
Tipo del documento:
Article